UPDATE 1-AstraZeneca pill slashes lung cancer progression in study
* Drug targets genetic mutation common in China, east Asia (Adds AstraZeneca comment, further details)
Nov 21 CSRA Inc :
* CSRA awarded $52 million contract to strengthen cyber infrastructure for DHS Source text for Eikon: Further company coverage:
LONDON, Dec 6 AstraZeneca's pill Tagrisso cut the risk of lung cancer progressing by 70 percent compared to standard chemotherapy in a major clinical trial, lifting prospects for a drug that is key to the company's ambitious long-term sales goals.
* Says unit Prinston Pharmaceutical in deal to buy Par Pharmaceutical's factory in North Carolina's Charlotte for $14 million